Natixis Advisors’s bluebird bio BLUE Stock Holding History

Natixis Advisors’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-773	Closed	-$540K	–	1214
2020 Q3	$540K	Buy	+773	New	+$603K	﹤0.01%	1036

Other funds holding BLUE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Natixis Advisors's BLUE Position: Q4 2020 in Review

Natixis Advisors sold out of bluebird bio (BLUE) in Q4 2020, closing a stake of 773 shares — an estimated $540K sold.

Natixis Advisors first reported a position in BLUE in Q3 2020 and held it in 1 quarter. The position peaked at $540K in Q3 2020. 262 funds tracked by Wall St. Rank hold BLUE as of Q4 2020.

Natixis Advisors reported no remaining bluebird bio position as of Q4 2020 after selling out during the quarter.
Natixis Advisors sold 773 bluebird bio shares in Q4 2020, an estimated $540K.
Natixis Advisors first reported a position in bluebird bio in Q3 2020 and held it in 1 quarter.
Natixis Advisors's bluebird bio position peaked at $540K in Q3 2020.
262 funds tracked by Wall St. Rank held bluebird bio as of Q4 2020.

Based on Natixis Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.